| Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma M Hus, N Grzasko, M Szostek, A Pluta, G Helbig, D Woszczyk, ... Annals of hematology 90, 1161-1166, 2011 | 64 | 2011 |
| The effect of β-carotene and its derivatives on cytotoxicity, differentiation, proliferative potential and apoptosis on the three human acute leukemia cell lines: U-937, HL-60 … T Sacha, M Zawada, J Hartwich, Z Lach, A Polus, M Szostek, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1740 (2), 206-214, 2005 | 38 | 2005 |
| Methods for freezing, thawing and viability estimation of hemopoietic stem cells Z Walter, M Szostek, D Weglarska, D Raguszewska, M Jabłoński, ... Przegla̧d lekarski 56, 34-39, 1999 | 16 | 1999 |
| Autoimmune-associated hemophagocytic syndrome/macrophage activation syndrome M Machaczka, W Sydor, M Rucinska, M Szostek, J Musial Autoimmune Disorders-Current Concepts and Advances from Bedside to …, 2011 | 15 | 2011 |
| Original article Transcoronary stem cell delivery using physiological endothelium-targeting perfusion technique: the rationale and a pilot study involving a comparison with … P Musiałek, W Tracz, A Skotnicki, K Żmudka, P Pieniążek, Z Walter, ... Kardiologia Polska (Polish Heart Journal) 64 (5), 489-498, 2006 | 15 | 2006 |
| 90Y-Zevalin®(90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon … W Jurczak, A Giza, M Szostek, A Hubalewska-Dydejczyk, ... Blood 108 (11), 2747, 2006 | 12 | 2006 |
| Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish … W Jurczak, AM Gruszka, AS Staszczak, M Dlugosz-Danecka, M Szostek, ... Leukemia & lymphoma, 2019 | 11 | 2019 |
| A fatal case of acquired hemophagocytic lymphohistiocytosis (macrophage activation syndrome) in the initial course of dermatomyositis with anti‐J o‐1 antibody S Bazan‐Socha, M Zolcinski, M Szostek, A Jurczyszyn, M Rucinska, ... International journal of rheumatic diseases 20 (12), 2171-2174, 2017 | 10 | 2017 |
| Plasma Cell Leukemia—Facts and Controversies: More Questions than Answers? A Suska, DH Vesole, JJ Castillo, SK Kumar, H Parameswaran, ... Clinical Hematology International 2 (4), 133-142, 2020 | 6 | 2020 |
| Beta-carotene regulates the expression of proapoptotic BAX and CAPN2 in HL-60, U-937 and TF-1-human acute myeloid leukemia cell lines; microarray, RQ-PCR and Western blot analysis T Sacha, M Zawada, J Dulińska-Litewka, Z Lach, M Szostek, M Bodzioch, ... Przeglad Lekarski 68 (5), 258-262, 2011 | 6 | 2011 |
| Lovastatin as salvage immumomodulatory therapy in patients with refractory and relapsed multipla myeloma. M Hus, N Grzasko, D Jawniak, M Szostek, A Dmoszynska Blood 106 (11), 449A-450A, 2005 | 3 | 2005 |
| Manageable and Transient Hematologic Toxicity Associated with 90Y-Ibritumomab Tiuxetan (90Y-Zevalin) Consolidation of FCM Chemotherapy in Mantle Cell Lymphoma (MCL) Patients. W Jurczak, M Szostek, A Giza, Z Rudzki, A Skotnicki Blood 106 (11), 4793, 2005 | 3 | 2005 |
| Detection of BCR-ABL translocation and different type of chimeric m-RNA in chronic myelogenous leukemia by single tube RT-PCR and the Sokal prognostic index T Sacha, J Dulak, D Hawrylecka, D Zmudzinska-Grochot, I Florek, ... CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY 24, 73-81, 1999 | 3 | 1999 |
| Characteristics of the hemopoietic stem cell and its biological marker--the CD34 molecule AB Skotnicki, M Jabłoński, M Szostek, M Libura Przeglad Lekarski 56, 17-21, 1999 | 3 | 1999 |
| Hematological toxicity of Ibritumomab (Zevalin) used as a consolidation strategy W Jurczak, A Giza, D Zimowska-Curylo, D Krochmalczyk, M Szostek, ... ANNALS OF ONCOLOGY 19, 247-247, 2008 | 2 | 2008 |
| Impaired Clonogenic Capacity Contributes to Bone Marrow Hypoplasia and Late Hematological Recovery after Zevalin in the Low-Grade NHL Patients. W Jurczak, M Szostek, Z Rudzki, D Krochmalczyk, J Wegrzyn, J Czyz, ... Blood, The Journal of the American Society of Hematology 104 (11), 4610-4610, 2004 | 2 | 2004 |
| Recovery of kidney function in a patient with multiple myeloma after using high cutoff dialyzers as a preparation for successful autologous stem-cell transplantation M Krzanowski, A Jurczyszyn, P Dumnicka, A Kraśniak, K Woziwodzka, ... Przegląd Lekarski 74 (12), 2017 | 1 | 2017 |
| Hematological toxicity of radioimmunotherpy with 90Y Ibritumomab W Jurczak, M Szostek, M Jakóbczyk, AS Staszczak, D Zimowska-Curyło, ... Przeglad Lekarski 69 (3), 107-114, 2012 | 1 | 2012 |
| Evaluation of transplantation material based on immunophenotype and in vitro clonogenic assays of hematopoietic stem and progenitor cells A Balana-Nowak, E Zdziłowska, M Szostek, AB Skotnicki Przeglad lekarski 56, 28-33, 1999 | 1 | 1999 |
| Reversing the poor prognosis of primary amyloid light‑chain amyloidosis with cardiac involvement A Jurczyszyn, R Rajtar-Salwa, D Sorysz, B Zawiślak, A Suska, M Szostek Pol. Arch. Med. Wew.(Online), 2022 | | 2022 |
